Transitioning to risk-based clinical trial management under ICH E6(R3)

Risk-based quality management (RBQM) is becoming central to clinical trial oversight, with ICH E6(R3) emphasising proportional, patient-focused approaches. Sponsors and CROs are moving away from rigid monitoring plans toward strategies that embed quality throughout trial design and execution.

Guide

NEW: The Ultimate Guide to Modern, Regulatory-Grade RBQM

Blog

ICH E6(R3), Demystified Part 4: Informed Consent

From Signature to System: Why E6(R3) Raises the Bar For years, informed consent has too often...

Blog

RBQM for the Mid-Market Explained

Mid-market sponsors are expected to meet the same ICH E6(R3) standards as large pharma, often with...

Blog

5 Myths Mid-Market Teams Believe About RBQM and What ICH E6(R3) Actually Requires

Risk-Based Quality Management (RBQM) is no longer a future-state concept. Under ICH E6(R3), it is a...